{"date":"2026-02-28","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7427-2026-02-28-1636-h45j6x","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2026-02-28","time":"16:36:52","subject":"公告本公司自主開發擁有全球開發權利的表觀遺傳免疫活化新藥GNTbm-38，向美國FDA遞交臨床一期試驗的IND申請已於02月27日(美國時間)核准。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2026-02-28 16:36，「公告本公司自主開發擁有全球開發權利的表觀遺傳免疫活化新藥GNTbm-38，向美國FDA遞交臨床一期試驗的IND申請已於0」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4166-2026-02-28-0658-1vx95gt","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2026-02-28","time":"06:58:07","subject":"公告本公司與INVAGEN PHARMACEUTICALS, INC.簽訂商業代理合約","clause":"第10款","fact_date":"2026-02-27","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2026-02-28 06:58，「公告本公司與INVAGEN PHARMACEUTICALS, INC.簽訂商業代理合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}